^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

AIM2 overexpression

i
Other names: AIM2, Absent In Melanoma 2, Interferon-Inducible Protein AIM2, PYHIN4
Entrez ID:
Related biomarkers:
1year
The Ednrb-Aim2-AKT axis regulates neural crest-derived melanoblast proliferation during early development. (PubMed, Development)
These results reveal the Ednrb-Aim2-AKT axis in regulating melanocyte development and suggest that Ednrb signaling functions as a negative regulator of Aim2, which inhibits the proliferation of melanoblasts in early development. These findings uncover a previously unreported role for Aim2 outside the inflammasome, showing that it is a significant regulator controlling NC stem cell-derived lineage development.
Journal
|
AIM2 (Absent In Melanoma 2) • EDNRB (Endothelin Receptor Type B) • MIR196B (MicroRNA 196b)
|
AIM2 overexpression
over1year
Inflammatory corpuscle AIM2 facilitates macrophage foam cell formation by inhibiting cholesterol efflux protein ABCA1. (PubMed, Sci Rep)
Overall, our study suggests that AIM2 is a reliable anti-inflammatory therapeutic target for AS. Inhibiting AIM2 expression may reduce foam cell formation and, consequently, inhibit the progression of AS plaques.
Journal
|
IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • ABCA1 (ATP Binding Cassette Subfamily A Member 1)
|
AIM2 overexpression
almost2years
Absent in melanoma 2 attenuates proliferation and migration and promotes apoptosis of human colorectal cancer cells by activating P38MAPK signaling pathway. (PubMed, Oncol Res)
Altogether, our achievements distinctly underscored AIM2's antitumor role in CRC. AIM2 overexpression inhibited proliferation and migration and induced apoptosis of CRC cells via activating P38MAPK signaling pathway, indicating AIM2 as a prospective and novel therapeutic target for CRC.
Journal
|
AIM2 (Absent In Melanoma 2)
|
AIM2 overexpression
2years
Prognostic and immunotherapeutic significance of immunogenic cell death-related genes in colon adenocarcinoma patients. (PubMed, Sci Rep)
Additionally, our study found that the suppression of AIM2 could significantly enhance the proliferation, invasion, and migration capabilities of colon cancer cells. In this research, we identified a novel prognostic signature suggesting that patients with higher AIM2 expression levels are more likely to respond favorably to immunotherapy.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
|
TMB-H • AIM2 overexpression